Sequence: FFLIGFFLIG-rrrrrrrrrrrr-amide (Pas2 = FFLIG-FFLIG; r12 = D-dodeca-arginine, amidated)
| Experiment Id | EXP001696 |
|---|---|
| Paper | Oligoarginine-Bearing Tandem Repeat Penetration-Accelerating Sequence Delivers Protein to Cytosol vi |
| Peptide | Pas2r12 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Final to cells typically 20 µM CPP (after 45 min treatment; see Figure 2b/Methods). |
| Rna Concentration | |
| Mixing Ratio | Simple mixing with protein cargo (e.g., EGFP:CPP 15 µM : 20 µM final to cells). |
| Formulation Format | Noncovalent CPP/protein complexes by simple mixing + incubation (no cross-linking required). |
| Formulation Components | CPP + protein cargo (EGFP or IgG) in Opti-MEM; then DMEM added for incubation. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEK293 |
| Animal Model | |
| Administration Route | |
| Output Type | protein cytosolic delivery (not RNA delivery) |
| Output Value | Cytosolic/nuclear distribution of EGFP observed by CLSM (up to ~36% of cells with cytosolic EGFP after 16 h). Also delivers Alexa488-IgG to cytosol (~14–18% of cells at optimized conditions). |
| Output Units | |
| Output Notes | Mechanism: energy-dependent uptake requiring actin polymerization; inhibited strongly by caveolae-mediated endocytosis inhibitors (genistein, MβCD) and by caveolin-1 knockdown. Note: a siRNA against caveolin-1 is used as a mechanistic tool and is delivered using Lipofectamine RNAiMAX (not by Pas2r12). |
| Toxicity Notes | MTT: mild viability decrease with increasing Pas2r12 concentration (e.g., ~85% at 20 µM; ~68% at 30 µM) in EGFP delivery condition. |
| Curation Notes |